Corporate & Investor Presentation

Proactive care to capture significant underpenetrated markets Chronic disease is the largest driver of healthcare spending in developed economies Sleep apnea Leading indicator, and a contributing factor, to many chronic illnesses More than 80% undiagnosed Demonstrated positive dose-response relationship between CPAP usage and lower healthcare costs • • • COPD Largely undiagnosed COPD sufferers in high-growth markets such as China, India, Brazil, and E. Europe >100M² Acute treatment costs to healthcare systems are large - Europe: €48B per year* - U.S.: ~$50B per year5 More than 3M people worldwide die each year due to COPD1 Asthma Significant opportunity to improve adherence and improve patient-physician interaction Leveraging Propeller for increased data related to symptom occurrence and acute triggers Opportunity to partner with patients, providers, pharmaceutical companies, and payors to drive improved quality of life 936M sleep apnea patients Total addressable market 380M COPD patients²,3 330M asthma patients6 Well-positioned to expand proactive treatment of chronic diseases 1World Health Organization. The top 10 causes of death: Fact sheet: No310 (2014, May) accessed 20 Jul 16 2 https://www.ncbi.nlm.nih.gov/pubmed/26755942 3 Company estimates based on World Health Organization estimates and Zhong et al. "Prevalence of Chronic Obstructive Pulmonary Disease in China" Respiratory and Critical Care 4 European Respiratory Society, European Lung White Book http://www.erswhitebook.org/chapters/the-economic-burden-of-lung-disease/accessed 20Jul16 5 Guarascio et al. Dove Med Press, 2013 Jun 17 6 World Health Organization. Chronic obstructive pulmonary disease (COPD): Fact sheet No315. 2015 accessed 20Jul16 10 © 2022 ResMed | Corporate & Investor Presentation - updated 27JAN22 ResMed

View entire presentation